Employees: 566
Size Medtide (3880.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $331M, the 859th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$18.55 on 18 Nov 2026.
Performance Over six months the shares fell 16.7%, against -31.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 14.0% over the last twelve months (peer median +5.7%); the operating margin is 35.9% (peer median -244.5%).
Valuation It trades at 10.5× forward earnings.
Capital Return on invested capital runs 18.8 points above its cost of capital (5.6% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$614M | HK$618M | HK$479M | HK$372M | HK$408M |
| Revenue growth | — | +29% | +29% | -9% | — |
| Gross profit | HK$381M | HK$392M | HK$271M | HK$199M | HK$234M |
| EBITDA | HK$254M | HK$280M | HK$173M | HK$126M | HK$162M |
| Net income | HK$187M | HK$236M | HK$64.2M | HK$54.0M | HK$62.8M |
| Free cash flow | -HK$74.1M | HK$149M | HK$107M | HK$36.6M | HK$48.6M |
| Capital expenditure | HK$216M | HK$141M | HK$24.3M | HK$61.5M | HK$107M |
| Total debt | n/a | HK$34.2M | HK$36.7M | HK$332M | HK$365M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3880.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.7% | -4.7% | 10th lowest of 20 |
| 6-month return | -16.7% | -31.0% | 5th highest of 20 |
| Distance from 52-week high | -42.0% | -54.6% | 4th highest of 20 |
| Revenue growth (TTM) | +14.0% | +5.7% | 5th highest of 13 |
| Operating margin | 35.9% | -244.5% | 2nd highest of 15 |
| Forward P/E | 10.5× | n/a | — |
| ROIC minus cost of capital | +18.8 pp | -63.8 pp | 3rd highest of 14 |
| EV / EBITDA | 5.8× | 12.4× | 3rd cheapest of 6 |
| Net debt / EBITDA | -4.5× | -1.1× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medtide 3880.HK | Hong Kong | $331M | -17% | +14% | 36% | 10.5× | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $326M | -53% | n/a | -57% | n/a | n/a | n/a |
| Larimar Therapeutics LRMR | United States | $337M | -9% | n/a | n/a | n/a | n/a | n/a |
| C4 Therapeutics CCCC | United States | $325M | -25% | +7% | -316% | n/a | n/a | n/a |
| GI Innovation 358570.KS | South Korea | $339M | -47% | +1,527% | -918% | n/a | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $341M | -19% | -63% | -1,388,360% | n/a | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $321M | -31% | n/a | n/a | n/a | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $319M | -79% | +395% | -173% | n/a | n/a | n/a |
| ProKidney PROK | United States | $314M | -38% | +4% | -24,830% | n/a | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $349M | n/a | n/a | n/a | n/a | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $350M | -36% | +3% | 10% | 18.1× | 4.7% | +11.9% |
| Nautilus Biotechnolgy NAUT | United States | $310M | +2% | n/a | -15,106% | n/a | n/a | n/a |
| Cuorips 4894.T | Japan | $309M | -10% | -80% | -1,765% | n/a | n/a | n/a |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | n/a | n/a | n/a |
| X4 Pharmaceuticals XFOR | United States | $304M | -21% | -50% | -474% | n/a | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $303M | -18% | +7% | 10% | 8.1× | 2.6% | +19.1% |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| Greenwich LifeSciences GLSI | United States | $302M | -25% | n/a | n/a | n/a | n/a | n/a |
| Galectin Therapeutics GALT | United States | $301M | +35% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | n/a | 0.6% | +725.2% |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | n/a | n/a | n/a |